Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.

ABSTRACT: AIMS/HYPOTHESIS:In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS:Changes from baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed in the EMPA-REG OUTCOME® trial (n?=?7020), pooled data from four 24-week placebo-controlled trials (n?=?2477) and a trial of empagliflozin vs glimepiride over 104 weeks (n?=?1545). Analyses were performed using data from all participants and by tertiles of baseline aminotransferases. RESULTS:In the EMPA-REG OUTCOME® trial, mean ± SE changes from baseline ALT at week 28 were -2.96?±?0.18 and -0.73?±?0.25 U/l with empagliflozin and placebo, respectively (adjusted mean difference: -2.22 [95% CI -2.83, -1.62]; p?AST) that is potentially consistent with a reduction in liver fat, especially when ALT levels are high.

SUBMITTER: Sattar N 

PROVIDER: S-EPMC6133166 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature